Tablet coating is one of the most consequential unit operations in solid dosage manufacturing. Whether a tablet is film-coated or sugar-coated determines its mechanical durability, moisture and light protection, taste-masking efficacy, dissolution profile, and patient acceptability — as well as the complexity, cost, and regulatory burden of the manufacturing process. Understanding the chemistry and engineering of both technologies is fundamental to making sound formulation and manufacturing decisions.
Film coating now accounts for the overwhelming majority of new pharmaceutical product development, driven by its speed, process controllability, and compatibility with continuous manufacturing platforms. Sugar coating, a centuries-old technique, persists in specific niches where its appearance, taste-masking depth, or pharmacopoeial specification makes it irreplaceable. Both technologies draw on distinct polymer chemistry, process engineering, and quality control science that are explored in detail below.
For companies entering pharmaceutical tablet manufacturing or scaling up an existing product, the choice of coating technology is not a cosmetic decision — it directly affects the design space of the dosage form, the capital equipment required, and the regulatory strategy for the product lifecycle. This article provides the technical and strategic grounding needed to make that decision well.
Overview of Tablet Coating: Purpose and Functional Classification
Tablet coating serves several distinct functional purposes that determine which technology is appropriate. At the most basic level, coating protects the tablet core from the environment — specifically from moisture, oxygen, and light, each of which can degrade chemically reactive active pharmaceutical ingredients (APIs) during storage. Beyond protection, coating is deployed for taste and odour masking, where the coating layer prevents direct contact between the bitter or malodorous drug substance and oral mucosal surfaces. For modified-release and enteric applications, the coating itself becomes the functional delivery element — controlling when and where the drug releases.
- Immediate-release protective coating — Thin polymer film applied primarily to improve appearance, improve shelf life, and enable product identification through colour and debossing.
- Taste-masking coating — Film or sugar coat that prevents drug dissolution in saliva; critical for paediatric and chewable formulations.
- Enteric coating — pH-dependent polymer barrier that prevents gastric dissolution and targets drug release to the small intestine.
- Modified-release coating — Rate-controlling membrane that modulates the rate of drug release independent of gastrointestinal pH.
- Sugar coating — Multi-layer sucrose-based process used for aesthetic enhancement, intense taste masking, and traditional formulation requirements.
Film Coating Polymer Chemistry
Film coating polymers must satisfy several simultaneous requirements: they must dissolve or disperse in a practical coating medium (water or organic solvent), form a continuous, flexible film on the tablet surface upon drying, adhere to the tablet core substrate, and deliver the required functional performance — whether that is moisture barrier, taste masking, or controlled dissolution. The most widely used immediate-release film coating polymer is hydroxypropyl methylcellulose (HPMC, Hypromellose), a semi-synthetic cellulose ether that combines excellent film-forming characteristics with a well-established regulatory safety and toxicological profile recognised across all major pharmacopoeias.
HPMC-based coating systems are typically applied from aqueous dispersions at solids concentrations of 10–15% w/w, using pre-formulated ready-to-disperse blends that include the polymer, a plasticiser (most commonly propylene glycol or polyethylene glycol 400), titanium dioxide as an opacifier, and iron oxide or lake pigments for colour. Plasticisers reduce the glass transition temperature (Tg) of the HPMC film below ambient temperature, allowing the film to remain flexible and crack-resistant during storage and packaging operations. The mechanical properties of the dried film — Young's modulus, elongation at break, and water vapour transmission rate — are sensitive to plasticiser type and concentration and must be verified during formulation development.
Polyvinyl alcohol (PVA)-based systems, commercially available in pre-formulated blends, offer improved moisture-barrier performance compared with HPMC because PVA films are significantly less permeable to water vapour at equivalent coating weights. This makes PVA-based coatings the preferred choice for moisture-sensitive drug substances where extended shelf life under high-humidity storage conditions is required. For enteric and delayed-release applications, methacrylic acid copolymers (EUDRAGIT L, S, and FS grades from Evonik) and cellulose acetate phthalate (CAP) provide pH-dependent solubility that underpins gastric resistance. HPMC acetate succinate (HPMCAS) is widely used in amorphous solid dispersion coatings because of its ability to sustain supersaturation.
| Polymer | Application | Coating Medium | Typical Weight Gain | Key Property |
|---|---|---|---|---|
| HPMC (Hypromellose) | IR protective / colour coat | Aqueous | 2–4% | Excellent film formation, broad regulatory acceptance |
| PVA (Polyvinyl Alcohol) | IR, moisture-sensitive APIs | Aqueous | 2–4% | Low WVTR, fast film formation |
| Ethylcellulose (EC) | Taste masking, MR membrane | Aqueous dispersion / solvent | 5–15% | Water-insoluble barrier, tunable with pore formers |
| Eudragit L100-55 / HPMC-AS | Enteric / pH-triggered release | Aqueous dispersion / solvent | 5–10 mg/cm² | Dissolves at pH ≥5.5 (L100-55) or pH ≥6.8 (S100) |
| HPMC Phthalate (HP-55) | Enteric coating | Solvent or aqueous | 5–10 mg/cm² | Dissolves at pH ≥5.5, high Tg |
Sugar Coating: Process Stages and Chemistry
Sugar coating is a multi-stage process that builds up discrete layers of sucrose-based coatings around a tablet core. The sequence begins with a subcoating step, where a seal coat of shellac or HPMC solution is first applied to the tablet core to protect it from the aqueous sugar syrup and to begin rounding the tablet's edges. This is followed by repeated applications of a heavy sugar syrup — typically 60–70% w/w sucrose — that are applied in alternating syrup and dusting powder cycles, with the dusting powder (often talc, calcium carbonate, or titanium dioxide) absorbing excess moisture between applications. The cumulative effect of multiple subcoating cycles is to build up a smooth, rounded layer that obscures the original tablet shape entirely.
After the subcoating phase is complete, smoothing syrups of progressively lower sucrose concentration and decreasing viscosity are applied to achieve a smooth surface. Colour coats are then applied using coloured syrups or aqueous dye solutions in multiple thin passes until a uniform, defect-free colour is achieved. The final step is polishing — a small quantity of carnauba wax, beeswax, or a blend of both is applied in a hot pan to create the characteristic high-gloss appearance of the finished sugar-coated tablet. The total weight gain from subcoating through polishing typically ranges from 30% to 50% of the uncoated core weight, which substantially increases tablet size, packaging requirements, and unit cost compared with film coating.
- Seal coating — Shellac or HPMC solution, 1–2 applications, protects core from moisture ingress during subsequent aqueous stages.
- Subcoating — Heavy sucrose syrup with dusting powder, 10–15 cycles, builds up bulk and rounds edges.
- Smoothing — Progressively lighter syrups, 5–10 passes, achieves surface regularity before colouring.
- Colour coating — Coloured sucrose syrup or aqueous dye solution, 20–30 passes, creates uniform pigmented surface.
- Polishing — Carnauba wax or beeswax blend in warm pan, 1–2 applications, produces high-gloss finish.
Coating Pan Process Parameters and Scale-Up
Film coating is performed in a perforated coating pan — a rotating drum with perforations in the pan wall through which drying air is drawn across the tumbling tablet bed. The spray system delivers coating solution through one or more binary nozzles (air-atomising guns) mounted on a spray arm inside the pan. The critical process parameters that must be controlled and monitored are inlet air temperature, outlet air temperature, inlet air volume, spray rate, atomisation air pressure, pan speed, and spray gun-to-bed distance. Of these, outlet air temperature is the primary controlled variable because it reflects the net energy balance of the process — if outlet temperature drops below target, the tablet bed is over-wet and at risk of sticking; if it rises above target, spray is drying before it reaches the tablets, producing a rough matte film.
Scale-up from laboratory pans (1–5 kg batch size) to pilot-scale (20–60 kg) and production pans (150–600 kg) requires systematic re-optimisation of all critical parameters because pan geometry, air distribution patterns, and spray-zone dynamics change significantly with scale. The spray rate-to-evaporative-capacity ratio must be maintained, but the absolute values of both must be recalculated. Guidance from ICH Q8(R2) on establishing a design space for coating processes has driven increased adoption of Process Analytical Technology (PAT) tools in coating — particularly near-infrared (NIR) sensors for real-time moisture measurement and thermographic cameras for mapping temperature uniformity across the tablet bed. These tools enable real-time release testing (RTRT) strategies that reduce or eliminate offline dissolution testing for batches manufactured within the validated design space.
| Parameter | Typical Range | Effect of Deviation |
|---|---|---|
| Inlet air temperature | 55–80°C | Too low → over-wetting, sticking; too high → spray drying, rough film |
| Outlet air temperature | 38–46°C | Primary control variable; must remain within ±2°C of target |
| Spray rate | 10–50 g/min (lab) / 200–800 g/min (production) | Too high → sticking, picking; too low → excess drying, bridging of logos |
| Pan speed | 8–20 rpm | Too slow → pooling, sticking; too fast → tablet attrition |
| Atomisation air pressure | 1.0–2.5 bar | Too high → fine spray, rough film (orange peel); too low → large droplets, sticking |
| Coating weight gain | 2–4% (IR film) / 5–10 mg/cm² (enteric) | Below minimum → incomplete coverage, functional failure; above maximum → dissolution delay |
Enteric Coating Technology: pH-Triggered Release
Enteric coatings exploit the pH gradient along the gastrointestinal tract to deliver targeted drug release. The polymer film remains intact and essentially impermeable at the low pH of gastric fluid (pH 1.0–2.0), protecting both the drug and the gastric mucosa from each other, and then rapidly dissolves when the coated tablet transitions to the higher pH environment of the proximal small intestine. The chemistry responsible for this behaviour is the presence of free carboxylic acid groups in the polymer backbone — in methacrylic acid copolymers, these groups constitute approximately 45–50% of the repeat unit composition. At gastric pH, the carboxylate groups are fully protonated (–COOH form) and the polymer is hydrophobic and insoluble. At intestinal pH, they ionise to the carboxylate form (–COO⁻), making the polymer water-soluble and triggering dissolution.
The dissolution pH threshold is a function of the specific polymer's acid content and substitution pattern. Eudragit L100-55 (methacrylic acid-ethyl acrylate copolymer 1:1) dissolves at pH ≥5.5, making it appropriate for targeting the proximal duodenum. Eudragit S100 (methacrylic acid-methyl methacrylate copolymer 1:2) dissolves at pH ≥7.0, appropriate for targeting the distal ileum and colon. HPMC phthalate (HP-55) dissolves at pH ≥5.5 and is favoured in many generic applications for its well-established regulatory profile. For enteric coatings, the minimum coating weight must be sufficient to produce a continuous, defect-free film with no pores or cracks that would allow gastric fluid ingress — typically 5–10 mg of polymer solids per cm² of tablet surface area, applied as an aqueous latex dispersion and cured at elevated temperature and humidity to complete film coalescence.
Film Coating vs Sugar Coating: Comparative Analysis
The choice between film and sugar coating involves a multi-dimensional assessment of technical, commercial, and regulatory factors. The table below summarises the principal differences across the criteria most relevant to pharmaceutical development and manufacturing decisions. For pharmaceutical product development projects, this comparison should be evaluated in the context of the API's chemical stability, the target patient population, the commercial market, and the available manufacturing infrastructure.
| Criterion | Film Coating | Sugar Coating |
|---|---|---|
| Typical weight gain | 2–5% | 30–50% |
| Process duration | 2–4 hours per batch | 1–3 days per batch |
| Tablet shape change | None (core shape retained) | Core shape obscured, rounded finish |
| Moisture protection per % weight gain | High (continuous film) | Moderate (porous sucrose layers) |
| Taste masking efficacy | Moderate (thin coat) | Excellent (thick shell) |
| Operator skill dependence | Low–moderate (automated pan) | High (real-time judgement required) |
| Equipment cost | High (perforated pan + spray system) | Moderate (conventional open pan) |
| Suitability for enteric / MR coating | Yes (polymer selection) | No (sucrose chemistry incompatible) |
| Diabetic patient suitability | Yes | No (sucrose content) |
| Regulatory acceptance for new applications | Preferred globally | Limited to specific compendial or traditional formulations |
Coating Defects: Root Causes and Corrective Actions
Coating defects are the primary source of batch rejections and process deviations in tablet manufacturing. Each defect type has a specific root cause traceable to one or more critical process parameters or formulation variables, and a systematic approach to investigation — using the relationship between spray rate, drying capacity, and pan speed as the primary diagnostic framework — is essential for efficient troubleshooting. The ASTM International standards and ICH Q8(R2) guidance on pharmaceutical development both reinforce the use of structured design of experiments to characterise and eliminate process-related coating defects during development rather than troubleshooting during manufacturing.
- Picking and sticking — Tablets adhering to each other. Root cause: spray rate exceeds evaporative capacity. Correction: reduce spray rate or increase inlet air temperature and volume.
- Orange-peel texture — Rough, matte, pitted surface. Root cause: droplets dry before coalescing on tablet surface. Correction: reduce atomisation air pressure or increase spray rate to maintain wet film at tablet surface.
- Logo bridging — Coating fills in debossed characters. Root cause: excessive coating weight or high polymer concentration. Correction: reduce weight gain target or spray solution concentration.
- Colour mottling — Non-uniform colour distribution. Root cause: uneven pigment dispersion in coating solution or inadequate tablet mixing. Correction: re-mill coating dispersion, increase pan speed, verify spray pattern coverage.
- Film cracking — Cracks appearing on coated tablets post-drying. Root cause: insufficient plasticiser, film Tg too high, or rapid thermal cycling. Correction: increase plasticiser level or type, reduce drying rate, allow adequate curing time.
- Blistering — Bubbles or raised areas on film surface. Root cause: moisture or volatile solvent trapped beneath coating. Correction: dry tablet cores thoroughly before coating, reduce spray rate, or lower solvent/water activity of coating solution.
Regulatory and GMP Considerations for Tablet Coating
Coating operations are subject to the full scope of current Good Manufacturing Practice (cGMP) requirements. The coating pan, spray system, and all product-contact surfaces must be validated for cleaning to prevent cross-contamination from residual coating pigments, APIs from previous products, or allergens (some coating systems include lactose or wheat-derived excipients that require specific cleaning validation and label disclosures). Cleaning validation for coating equipment must demonstrate that residual levels of all cleaning-relevant substances fall below calculated health-based exposure limits (HBELs) consistent with the approach outlined in EMA guideline EMA/CHMP/CVMP/SWP/169430/2012 on setting health-based exposure limits.
For the solid dosage formulation regulatory submission, the coating process must be described within the product design space established under ICH Q8(R2), with the effect of coating weight, process parameters, and polymer lot variability on in vitro dissolution characterised and bounded. Post-approval changes to coating composition or process parameters are governed by SUPAC-SS (for immediate-release) and SUPAC-MR (for modified-release) guidance documents from FDA, which classify changes by risk level and specify whether prior-approval supplements, changes-being-effected supplements, or annual reports are required. For enteric and modified-release coatings, dissolution testing must be repeated whenever a Level 2 or Level 3 coating change is implemented, and bioequivalence may be required for Level 3 changes affecting drug release. Consulting with experienced pharmaceutical formulation development services partners early in the coating technology selection process can prevent costly late-stage regulatory surprises.
Frequently Asked Questions
What is the fundamental difference between film coating and sugar coating for tablets?
Which polymer systems are most widely used in aqueous film coating?
What causes tablet coating defects such as picking, sticking, and orange-peel texture?
How does enteric coating prevent drug release in the stomach?
What are the key process parameters in a perforated coating pan that must be controlled?
What regulatory requirements apply to tablet coating excipients and processes?
When is sugar coating still preferred over film coating in modern pharmaceutical development?
Developing or Scaling a Coated Tablet Product?
Global Formulation provides end-to-end pharmaceutical tablet coating development support — from polymer system selection and coating process design to scale-up strategy, regulatory documentation, and technology transfer to contract manufacturers. Whether you are developing a new enteric-coated formulation, troubleshooting a coating defect at commercial scale, or transferring a film coating process to a new site, our team brings deep process development experience to your project.
Discuss Your Coating Project
Absar Khan
Absar Khan is the Founder and Lead Consultant at Global Formulation, specialising in pharmaceutical, cosmetic, and industrial chemical product development. With hands-on experience across solid dosage formulation, coating technology, aerosol systems, and lubricant chemistry, Absar helps entrepreneurs and manufacturers develop, scale, and commercialise formulated chemical products. Connect on LinkedIn.